Due to its rapid growth and potential to add to the respiratory virus burden in Northern Hemisphere countries, the World Health Organization (WHO) today designated JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest.
Over the past month, the proportion of JN.1 viruses has rapidly increased, rising from 3.3% in early November to 27.1% by early December. Countries reporting the highest proportions include France, the United States, Singapore, Canada, and the United Kingdom.
The fact that JN.1 is responsible for a growing portion of infections suggests it is either more contagious or better at getting past our bodies’ immune defenses than previous iterations of the virus, the CDC says. But there is no evidence that it causes more severe disease. The World Health Organization (WHO) has not labeled JN.1 a variant of concern—that is, a new strain of the SARS-CoV-2 virus with potential for increased severity; decreased vaccine effectiveness; or substantial impacts on health care delivery.
In the 18 months after a serious COVID-19 or seasonal influenza infection, patients are at a significant increased risk of death, hospital readmission, or health problems affecting a number of organs, though COVID patients are hit harder, according to a study published ...in The Lancet Infectious Diseases.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/3WI3IIT3CNOZDBZ6NJGZ5CLNLU.jpg)
Recent Comments